590 results about "Systemic lupus" patented technology

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with SLE (NPSLE) and for determining whether an SLE subject is at risk of developing a neuropsychiatric disease.

The invention discloses a systemic lupus erythematosus assessment method and device based on multi-modal medical map and medical knowledge fusion, terminal equipment and a medium, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring multi-dimensional medical indexes of a patient, and constructing a multi-modal medical knowledge graph of the patient associated with the indexes; pre-training the self-supervised graph neural network to obtain a patient and medical index embedding vector; grouping and constructing a feature subset combination according to medical knowledge, and training and selecting an optimal sub-model; dynamically weighting and fusing the prediction probabilities of the sub-models to obtain a comprehensive prediction probability; and screening the key indexes based on the embedded vector and quantifying the activity evaluation contribution degree of the key indexes to obtain an activity comprehensive score. The systemic lupus erythematosus evaluation method improves the accuracy and robustness of preliminary evaluation of systemic lupus erythematosus, solves the problems of data missing and sample imbalance, and is explainable in output evaluation, adaptive to primary medical treatment and capable of supporting hierarchical diagnosis and treatment.

The invention discloses a systemic lupus erythematosus interaction management method based on patient sign data modeling, and particularly relates to the field of lupus erythematosus interaction management, which comprises the following steps: collecting basic data and sign data of a patient, generating a standardized basic data set and an integrity sign data set, feature combination, feature correlation detection and factor extraction are executed, a potential feature space representing patient features is constructed, and static health behavior feature modeling is achieved; the method comprises the following steps: acquiring nurse-patient interaction behavior data, generating a preliminary interaction data set, executing interaction feature extraction and activeness judgment, and generating a standardized interaction feature matrix; a multi-dimensional feature vector and dynamic health behavior link is constructed based on patient sign data and interactive behavior features, and time sequence prediction and response feedback closed-loop optimization are combined, so that dynamic management and individualized intervention of active health behaviors of systemic lupus erythematosus patients are realized.

The invention discloses a detection method of a systemic lupus erythematosus immune spectrum based on full spectrum flow cytometry, and relates to the technical field of cell detection, and the detection method comprises the following steps: providing a fluorescein coupling antibody of a detection index; carrying out antibody titration on the fluorescein coupling antibody to obtain a dyeing concentration; the method comprises the following steps: carrying out surface staining on peripheral blood mononuclear cells of an SLE patient by adopting a fluorescein coupled antibody, carrying out intracellular mitochondrial superoxide staining, and resuspending in a detection solution to obtain a test sample; carrying out sample loading test on the test sample and the prepared single staining reference sample and negative sample, and collecting and analyzing particle information; and performing enclosure and dimension reduction analysis on the analyzed data to obtain a systemic lupus erythematosus immune spectrum and a cell activation state analysis result. According to the application, dozens of immune cell subtypes and activation states thereof in SLE can be detected under the condition of a single-tube sample, an SLE patient immune map is constructed, and a reference is provided for evaluating disease progression and formulating a treatment scheme.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

The invention discloses a method for constructing a Ddx58-R109C point mutation mouse model by using a CRISPR / Cas9 gene editing technology and an application of the Ddx58-R109C point mutation mouse model. The method comprises the following steps: (1) target construction: searching a CDS region of a Ddx58 gene, determining an exon part, and determining a gene mutation site; (2) obtaining a fertilized egg, and injecting Cas9mRNA, gRNA and donor oligo into the fertilized egg of the C57BL / 6J mouse together in vitro through a microinjection technology to obtain an F0-generation hybrid mouse; (3) mating the F0-generation hybrid mouse with the wild type mouse to obtain an F1-generation mouse; (4) the F1-generation heterozygous mice which are identified to be positive are subjected to mating, and homozygous Ddx58-R109C mutant type and wild type mice can be obtained by breeding obtained offspring; (5) phenotypic analysis shows that Ddx58-R109C point mutation mice can have pathological changes of systemic lupus erythematosus and lupus nephritis; the invention can provide an effective research approach and method for researchers to deeply explore the action mechanism of Ddx58-R109C mutation in diseases, and has important significance for explaining the pathogenesis of systemic lupus erythematosus and researching and developing targeted therapeutic drugs.

The use of dual-target CAR-T cells in treating systemic lupus erythematosus and other B-cell autoimmune diseases is provided. The first target of the chimeric antigen receptor is CD19, the second target is BCMA, and specifically, the chimeric antigen receptor is a chimeric antigen receptor with a Loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

To provide a compound which is a novel proline derivative, and to provide a pharmaceutical composition comprising the compound for the treatment of diseases, for example, systemic lupus erythematosus.SOLUTION: A pharmaceutical composition comprises, as a cGAS inhibitor, a compound which is a novel proline derivative of formula (I) (where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined in claim 1), or a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

The invention relates to the technical field of medical data processing, and discloses a construction method and application of a systemic lupus erythematosus activity evaluation model. Expression level data of CD177 on the surface of neutrophil, anti-dsDNA antibody titer data, anti-dsDNA antibody concentration data, complement C3 concentration data and complement C4 concentration data are combined, a machine learning algorithm is utilized, and the systemic lupus erythematosus activity evaluation model is constructed. A high-precision systemic lupus erythematosus activity evaluation model is obtained through training, systemic lupus erythematosus activity can be evaluated efficiently, comprehensively and accurately, and an SLE patient is effectively assisted in seeing a doctor in time and making a correct treatment decision.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention discloses an E-CAR-NK cell for treating systemic lupus erythematosus and application of the E-CAR-NK cell, and belongs to the technical field of genetic engineering.A CD19 and BCMA double-target E-CAR is adopted for modifying an NK cell, and the E-CAR-NK cell is obtained; the CD19 and BCMA double-target E-CAR is composed of the following modules: a CD8 signal peptide, a CD19 scFv, a Linker, a BCMA scFv, a CD8 Hinge region, an NKG2D transmembrane region, a CD3 epsilon signal transduction region, a DAP12 costimulatory region, a 2B4 costimulatory region, and a CD3 zeta signal transduction region. Compared with a common CAR-NK cell, the E-CAR-NK cell disclosed by the invention has higher antigen sensitivity and better continuous killing ability, so that the treatment effect of SLE is improved, and the E-CAR-NK cell has lower side effects and higher safety.

The invention discloses application of docosapentaenoic acid or medicinal salt thereof in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The invention aims to provide novel application of docosapentaenoic acid in treatment of systemic lupus erythematosus. In view of various immune abnormalities existing in the systemic lupus erythematosus morbidity process, the docosapentaenoic acid has potential application value in the field of systemic lupus erythematosus treatment due to the effects of regulating immune cell functions and improving immune microenvironment.

The invention provides a biomarker for diagnosing systemic lupus erythematosus and application of the biomarker. According to the application disclosed by the invention, the expression of Ferritin in neutrophil of a systemic lupus erythematosus patient is found to be obviously reduced and is improved after treatment, the neutrophil has disease specificity and cell specificity, and the Ferritin in the neutrophil has important significance on clinical diagnosis or auxiliary diagnosis of systemic lupus erythematosus and disease condition evaluation.

The invention discloses a systemic lupus erythematosus molecular diagnosis marker based on neutrophil characteristics. The invention provides application of a substance for detecting the expression quantity of an IFIH1 gene and / or a CFLAR gene in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of systemic lupus erythematosus. The invention also provides an application of a substance for detecting the relative expression quantity of the IFIH1 gene and the CFLAR gene and a carrier loaded with the following combined index C value model formula in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of systemic lupus erythematosus. The specific gene expression marker IFIH1 and / or CFLAR of the neutrophile granulocyte is selected by focusing the unique change of the SLE neutrophile granulocyte to assist the clinical early-stage identification and diagnosis of the SLE, and an IFIH1 and CFLAR combined diagnosis model is constructed, so that the diagnosis or screening of the SLE is realized; the kit has high sensitivity and specificity.

The invention discloses a traditional Chinese medicine composition for preventing / treating systemic lupus erythematosus and application thereof.The traditional Chinese medicine composition is reasonably combined according to etiology and pathogenesis of systemic lupus erythematosus, pseudo-ginseng, ginseng, glossy privet fruit and syngnathus serve as monarch drugs, and the traditional Chinese medicine composition has the effects of promoting blood circulation to remove blood stasis, nourishing the liver and tonifying the kidney and directly tonifying yin deficiency of the liver and the kidney; salvia miltiorrhiza, safflower, peach kernel, American ginseng, codonopsis pilosula, prepared rhizome of rehmannia, wolfberry, mulberry and panax japonicus are taken as ministerial drugs and are matched to assist the monarch drugs and clear stasis heat, cornu cervi pantotrichum, herba epimedii, hippocampus, pericarpium citri reticulatae, polygonum multiflorum, angelica sinensis, radix paeoniae alba, rhizoma polygonati and dog kidney are taken as adjuvant and conductant drugs and assist the monarch and ministerial drugs to harmonize yin and yang, all the drugs are matched and have a synergistic effect, and the effects of nourishing kidney and replenishing essence, reinforcing qi and nourishing yin, promoting blood circulation to remove meridian obstruction, warming yang and removing stasis can be achieved. The traditional Chinese medicine can treat both symptoms and root causes, and can effectively treat systemic lupus erythematosus.

The invention discloses a preparation method and application of an astragalus flavonoid extract with an effect of treating systemic lupus erythematosus, and belongs to the technical field of pharmaceutical preparations. The preparation method disclosed by the invention comprises the following steps: screening components for treating systemic lupus erythematosus target protein in astragalus membranaceus by adopting reverse network pharmacology; the preparation method comprises the following steps: preparing an astragalus flavonoid substance by adopting an ultrasonic-assisted deep eutectic solvent method, and extracting the astragalus flavonoid substance by using ethyl acetate to obtain an astragalus flavonoid ethyl acetate extract; preparing magnetic nanoparticles of which the surfaces are adsorbed with the target protein; and carrying out micromolecule fishing on the astragalus flavone ethyl acetate extract by adopting the magnetic nanoparticles, so as to obtain the astragalus flavone extract with the effect of treating systemic lupus erythematosus. The radix astragali flavonoid extract prepared by the invention has a higher curative effect on systemic lupus erythematosus, and has a better effect than the existing medicine under the same dosage.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

To provide compounds as new proline derivatives, and to provide a pharmaceutical composition comprising the compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis, non-alcoholic steatohepatitis, interstitial lung disease and idiopathic pulmonary fibrosis.SOLUTION: There are provided new proline derivatives of formula (I) as cGAS inhibitors, or pharmaceutical compositions comprising a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

The invention relates to a cyclopeptide inhibitor aiming at human STING (stimulating interferon gene) and application of the cyclopeptide inhibitor. The cyclic peptide can specifically bind to and inhibit activation of human STING. The invention also provides a nanoparticle delivery system for loading the cyclopeptide on a cationic polymer PBAE and an amphiphilic polymer pDMA-pEPEMA, and a preparation method of the nanoparticle delivery system. The cyclic peptide and the nanoparticles thereof can be used for preparing medicines for treating autoimmune diseases (such as systemic lupus erythematosus and the like) caused by excessive activation of the cGAS-STING signal pathway. Compared with the existing small molecule STING inhibitor, the cyclopeptide inhibitor provided by the invention has higher specificity, stability and inhibition effect.

The invention belongs to the field of new application of medicines, and particularly relates to application of SIRT4-IN-1 in preparation of medicines for treating autoimmune diseases. It is found for the first time that SIRT4-IN-1 reduces the activation degree of immune response induced by HSV-1 virus infection by up-regulating acetylation modification of cGAS, inhibits abnormal activation of immune response in Trex1 deficient mouse cells and peripheral blood mononuclear cells of systemic lupus erythematosus patients, and improves abnormal activation of autoimmune response. The invention provides a new candidate drug for clinical treatment of systemic lupus erythematosus.

The present invention relates methods of producing B cell depletion in autoimmune diseases. More specifically, the invention shows the use of CD-19 bispecific targeting molecules to effectively treat autoimmune disorders such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's disease (SjD).

The invention belongs to the field of immune cell therapy, and particularly relates to application of a double-target CAR-T cell to treatment of systemic lupus erythematosus and other B-cell autoimmune diseases. A first target point of the chimeric antigen receptor is CD19, a second target point of the chimeric antigen receptor is BCMA, and the chimeric antigen receptor with the Loop structure is specifically the chimeric antigen receptor with the Loop structure, and the structure of the chimeric antigen receptor with the Loop structure is shown as follows: L-VL, CD19-VH, BCMA-VL, BCMA-VH and CD19-H-TM-C-CD3zeta; the BCMA-CD19 CAR-T cell transduced by the chimeric antigen receptor can more comprehensively block the way of generating the autoantibody in the process of targeting CD19 and BCMA, and can more completely cover B cells, plasma mother cells and plasma cells which generate the autoantibody and are in a plurality of differentiation stages; therefore, the double-target CAR-T therapy designed on the basis of the concept can be used for treating refractory SLE, and is expected to obtain quicker relieving and deeper and lasting curative effects.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

The disclosure relates to methods and compositions for the treatment of Systemic Lupus Erythematosus (SLE).

Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative lesions represent the most severe form of lupus nephritis (LN) and often lead to kidney failure and death. Mucosal-associated invariant T (MAIT) are a subset of innate-like T cells that recognize microbial-derived ligands from the riboflavin synthesis pathway. Now the inventors analyzed the phenotype and function of peripheral blood MAIT cells by flow cytometry in 26 patients with LN and in a control group of 16 healthy volunteers. The inventors found that MAIT cell frequencies are markedly reduced in blood of LN patients. More particularly, among LN patients, baseline MAIT cell frequency, Ki-67 expression evaluating proliferative activity and granzyme B production measuring cytotoxicity represent promising prognostic factors of renal response one year after induction therapy. In conclusion, the inventors showed that baseline frequency and cytotoxic profile of MAIT cells may represent a promising prognostic factor of renal remission one year after induction therapy.

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and / or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).